DIFLUCAN 2 MG — DIN 00891835
FLUCONAZOLE : 2 MG · PFIZER CANADA ULC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is DIFLUCAN?
DIFLUCAN 2 MG contains FLUCONAZOLE : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 00891835, held by PFIZER CANADA ULC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 31-Dec-1990. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DIFLUCAN used for?
Oropharyngeal/esophageal candidiasis; systemic candidal infections (UTI, peritonitis, pneumonia); cryptococcal meningitis; prevention of cryptococcal meningitis in AIDS; prophylaxis in BMT patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Fluconazole cost around the world?
Fluconazole is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Morocco | PPV (public price) | 29 | 93 | MAD███.██ |
| Greece | producer price (ex-factory) | 67 | 67 | EUR███.██ |
| United States | acquisition | 6 | 64 | USD███.██ |
| South Africa | single exit price | 50 | 62 | ZAR███.██ |
| Saudi Arabia | public | 33 | 37 | SAR███.██ |
| United Arab Emirates | public | 16 | 18 | AED███.██ |
| Australia | ex-manufacturer | 9 | 16 | AUD███.██ |
| Bahrain | retail (max) | 12 | 16 | BHD███.██ |
| United Kingdom | hospital | 8 | 8 | GBP███.██ |
381 pack listings across 230 brand entries and 8 price bases, refreshed 08 Sep 2026. Ranges span every Fluconazole pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Fluconazole in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
29 holders have a Canadian DIN containing Fluconazole, across 71 DINs, of which 29 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 8 | 4 | APO-FLUCONAZOLE, APO-FLUCONAZOLE-150, FLUCONAZOLE 150, FLUCONAZOLE TABLETS | Sourceable in Canada |
| PFIZER CANADA ULC | 5 | 3 | DIFLUCAN, DIFLUCAN ONE | Sourceable in Canada |
| SANIS HEALTH INC | 3 | 3 | FLUCONAZOLE, FLUCONAZOLE-150 | Sourceable in Canada |
| TEVA CANADA LIMITED | 6 | 2 | ACT FLUCONAZOLE, FLUCONAZOLE INJECTION, NOVO-FLUCONAZOLE, TEVA-FLUCONAZOLE | Sourceable in Canada |
| PHARMASCIENCE INC | 5 | 2 | FLUCONAZOLE-150, PMS-FLUCONAZOLE, PMS-FLUCONAZOLE-150 | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 3 | 2 | MYLAN-FLUCONAZOLE | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 2 | 2 | FLUCONAZOLE | Sourceable in Canada |
| BAYER INC | 2 | 1 | CANESORAL, CANESORAL COMBI | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 1 | JAMP FLUCONAZOLE 150 MG, JAMP-FLUCONAZOLE | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 2 | 1 | RIVA-FLUCONAZOLE | Sourceable in Canada |
| PRO DOC LIMITEE | 2 | 1 | PRO-FLUCONAZOLE | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 1 | FLUCONAZOLE INJECTION, FLUCONAZOLE INJECTION SDZ | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Tablets: Bottles of 50 or 100. Oral Suspension: 35 mL HDPE bottles (350 mg total). Injection: 100 mL glass bottles (200 mg). |
| Storage | Not explicitly detailed in provided text snippet (refers to section 11), but mentions inspecting injection for cloudiness/precipitation. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Fluconazole |
|---|---|
| ATC code | J02AC01 |
| AHFS class | 08:14.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00891835 |
|---|---|
| DIN (unpadded, as printed on some documents) | 891835 |
| Brand name | DIFLUCAN |
| Generic / active ingredient | FLUCONAZOLE : 2 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | J02AC01 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J02AC |
| Current status | MARKETED |
| Status date | 31-Dec-1990 |
| Original market date | 1990-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 100-400 mg daily depending on indication. Children: 3-12 mg/kg daily. Loading dose of twice the daily dose is recommended on Day 1. Administered orally or IV.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to fluconazole or related azoles. Co-administration with drugs that prolong QT interval and are metabolized by CYP3A4 (e.g., erythromycin, pimozide, quinidine).
Warnings and precautions
Serious hepatic toxicity; exfoliative skin disorders (DRESS, SJS); QT prolongation/Torsade de Pointes; adrenal insufficiency; superinfections with non-albicans Candida (e.g., C. auris).
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
29 of 71 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT FLUCONAZOLE | 100 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02281279 |
| ACT FLUCONAZOLE | 50 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02281260 |
| AG-FLUCONAZOLE | 150 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | 02555891 |
| APO-FLUCONAZOLE | 100 MG | TABLET | APOTEX INC | MARKETED | 02237371 |
| APO-FLUCONAZOLE | 50 MG | TABLET | APOTEX INC | MARKETED | 02237370 |
| APO-FLUCONAZOLE-150 | 150 MG | CAPSULE | APOTEX INC | MARKETED | 02241895 |
| BIO-FLUCONAZOLE | 150 MG | CAPSULE | BIOMED PHARMA | MARKETED | 02462168 |
| CANESORAL | 150 MG | CAPSULE | BAYER INC | MARKETED | 02311690 |
| DIFLUCAN | 50 MG / 5 ML | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02024152 |
| DIFLUCAN ONE | 150 MG | CAPSULE | PFIZER CANADA ULC | MARKETED | 02141442 |
2 · Same class — other molecules in ATC J02AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Fluconazole | ACT FLUCONAZOLE · AG-FLUCONAZOLE · APO-FLUCONAZOLE · APO-FLUCONAZOLE-150 · +35 more | 71 | 29 | Yes |
| Voriconazole | ACH-VORICONAZOLE · APO-VORICONAZOLE · AURO-VORICONAZOLE · JAMP VORICONAZOLE · +7 more | 27 | 11 | Yes |
| Posaconazole | APO-POSACONAZOLE · GLN-POSACONAZOLE · JAMP POSACONAZOLE · MINT-POSACONAZOLE · +3 more | 9 | 8 | Yes |
| Itraconazole | JAMP ITRACONAZOLE ORAL SOLUTION · MINT-ITRACONAZOLE · ODAN ITRACONAZOLE · SPORANOX | 5 | 3 | Yes |
| Isavuconazole | CRESEMBA | 3 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J02A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J02AX | Anidulafungin · Caspofungin · Micafungin | 25 | 12 |
| J02AA | Amphotericin B | 7 | 2 |
| J02AB | Ketoconazole | 5 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DIFLUCAN called?
The same molecule, Fluconazole, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| CANAFLUCAN | Latin | Morocco |
| NOMYC | Latin | Morocco |
| MYNAZOL | Latin | Morocco |
| FLUCAZOL | Latin | Bahrain, Morocco |
| Aspen Fluconazole | Latin | South Africa |
| FONGICAN | Latin | Morocco |
| MYCOFLU | Latin | Morocco |
| TRINOMYC | Latin | Morocco |
| CANDICID | Latin | Morocco |
| Fluconazole Sandoz | Latin | Australia |
| FLUGIZOL | Latin | Morocco |
| FLUMYK | Latin | Morocco |
| IMIDAZOL | Latin | Morocco |
| Ozole | Latin | Australia |
| STARZOL | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.